Table 1. Frequency of seroconversion to antibody-positivity and development of diabetes according to age at seroconversion.
| Relatives | Age group | ||
|---|---|---|---|
| 0 - 9 years | 10 - 19 years | 20 - 39 years | |
| Total number; n | 2581 | 2055 | 2534 |
| Initially Ab-; n | 2444 | 1934 | 2413 |
| Ab+ relatives | |||
| - Ab+ at baseline; n (% of total) | 137 (5.3) | 121 (5.9) | 121 (4.8) |
| persistently Ab+; n (% of total) | 105 (4.1) | 94 (4.6) | 90 (3.6) |
| transiently Ab+; n (% of total) | 32 (1.2) | 27 (1.3) | 31 (1.2) |
| - Seroconverters; n (% of initially Ab-)a | 83 (3.4) | 79 (4.1) | 62 (2.6) |
| persistently Ab+; n (% of initially Ab-)b | 50 (2.0) | 39 (2.0) | 29 (1.2) |
| transiently Ab+; n (% of initially Ab-) | 33 (1.4) | 40 (2.1) | 33 (1.4) |
| Diabetes | |||
| - Ab+ at baseline; n (% of group)c | 56 (41) | 32 (26)d | 21 (17)e |
| persistently Ab+; n (% of group)c | 56 (53) | 32 (34)f | 20 (22)d |
| transiently Ab+; n (% of group) | 0 (0) | 0 (0) | 1 (3.2) |
| - Seroconverters; n (% of group)g | 18 (22) | 7 (8.9) | 5 (8.1) |
| persistently Ab+; n (% of group)g | 18 (36) | 6 (15) | 4 (14) |
| transiently Ab+; n (% of group) | 0 (0) | 1 (2.5) | 1 (3.0) |
| Median (IQR)h follow-up from Ab+ | |||
| - Ab+ at baseline; months | 74 (43-124) | 77 (36-124) | 62 (38-112) |
| persistently Ab+; months | 64 (37-110) | 62 (36-115) | 61 (37-122) |
| transiently Ab+; months | 107 (61-140) | 113 (71-139) | 64 (48-100)i |
| - Seroconverters; n (% of initially Ab-)b | 59 (25-92) | 48 (20-96) | 59 (24-89) |
| persistently Ab+; months | 53 (21-84) | 47 (16-96) | 60 (14-115) |
| transiently Ab+; months | 72 (34-100) | 49 (23-96) | 59 (25-88) |
a
Overall p = 0.020;
b
Overall p = 0.042;
c
Overall p < 0.001;
d
p= 0.015,;
e
p< 0.001,
f
p< 0.010 vs. age group 0-9 years;
g
Overall p = 0.027; Threshold for significance: overall p < 0.05/18 or p < 0.0028; for differences among age groups: p < 0.05/3 or p < 0.017 (Bonferroni correction);
h
Interquartile range;
i
follow-up time also limited by age limit